Letermovir
As of the edition of 20 October 2026, Letermovir is a small molecule: marketed, first approved in 2017 (CA); US protection ends in 2031.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Small molecule
- Brand name
- Prevymis
- First approved
- 1 November 2017 (CA)
- Approvals on record
- 19 in 6 regions
- Holder of the most recent approval
- Merck & Co.
- Registered trials
- 48, 1 stopped early
- Disease areas
- Infections; Blood and lymph; Cancer; Immune system; Urinary and reproductive; Heart and blood vessels
US protection
US protection ends in 2031.
The last listed US exclusivity ends in 2031. The application that gives this date is held by Merck & Co..
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product38 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 38 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 3 | 3 | 0 |
| Phase 1 | 4 | 1 | 3 | 0 |
| Phase 2 | 17 | 6 | 7 | 1 |
| Phase 3 | 13 | 6 | 6 | 0 |
| Phase 4 | 5 | 1 | 3 | 0 |
| All trials | 48 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Applicant and Lead sponsor of trials | 2014 to now |